KRAS and non-small cell lung carcinoma: Mahoney et al. investigated the crosstalk between ERK1/2 and mTOR pathways in non-small cell lung cancer cells with LKB1 and KRAS mutations suggesting that the inhibition of ERK1/2 can lead to the suppression of mTOR signaling [56].